| Year |
Citation |
Score |
| 2020 |
Ta HQ, Dworak N, Ivey ML, Roller DG, Gioeli D. AR phosphorylation and CHK2 kinase activity regulates IR-stabilized AR-CHK2 interaction and prostate cancer survival. Elife. 9. PMID 32579110 DOI: 10.7554/Elife.51378 |
0.446 |
|
| 2020 |
Ta HQ, Dworak N, Ivey ML, Roller DG, Gioeli D. Author response: AR phosphorylation and CHK2 kinase activity regulates IR-stabilized AR–CHK2 interaction and prostate cancer survival Elife. DOI: 10.7554/Elife.51378.Sa2 |
0.407 |
|
| 2019 |
Ta HQ, Whitworth H, Yin Y, Conaway M, Frierson HF, Campbell MJ, Raj GV, Gioeli D. Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth. Molecular Cancer. 18: 113. PMID 31253147 DOI: 10.1186/S12943-019-1039-6 |
0.349 |
|
| 2018 |
Ta HQ, Dworak N, Sleppy R, Allende JA, Gioeli D. Abstract 3747: Translating the functional interactions of checkpoint kinase 2 and the androgen receptor into more effective therapies for the treatment of prostate cancer Cancer Research. 78: 3747-3747. DOI: 10.1158/1538-7445.Am2018-3747 |
0.432 |
|
| 2016 |
Ta HQ, Jackson SR, Whitworth H, Bhadel S, Gioeli D. Abstract 979: Identification of a novel long noncoding RNA within the LCK gene locus that regulates prostate cancer cell growth Cancer Research. 76: 979-979. DOI: 10.1158/1538-7445.Am2016-979 |
0.413 |
|
| 2015 |
Ta HQ, Ivey ML, Frierson HF, Conaway MR, Dziegielewski J, Larner JM, Gioeli D. Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth. Cancer Research. 75: 5093-105. PMID 26573794 DOI: 10.1158/0008-5472.Can-15-0224 |
0.428 |
|
| 2015 |
Ta HQ, Ivey ML, Frierson HF, Conaway MR, Dziegielewski J, Larner JM, Gioeli D. Abstract 5049: Checkpoint kinase 2 is a novel regulator of prostate cancer cell growth Cancer Research. 75: 5049-5049. DOI: 10.1158/1538-7445.Am2015-5049 |
0.492 |
|
| 2014 |
Ta HQ, Gioeli D. The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer. Endocrine-Related Cancer. 21: R395-407. PMID 25096064 DOI: 10.1530/Erc-14-0217 |
0.426 |
|
| 2014 |
Koryakina Y, Ta HQ, Gioeli D. Androgen receptor phosphorylation: biological context and functional consequences. Endocrine-Related Cancer. 21: T131-45. PMID 24424504 DOI: 10.1530/Erc-13-0472 |
0.416 |
|
| 2013 |
Ta HQ, Ivey ML, Gioeli D. Abstract 3577: The role of Checkpoint Kinase 2 in the regulation of androgen receptor signaling and prostate cancer cell growth during progression to castration resistance. Cancer Research. 73: 3577-3577. DOI: 10.1158/1538-7445.Am2013-3577 |
0.483 |
|
| 2010 |
Ta HQ, Ray BJ, Bouton AH. Abstract 3177: Cas overexpression in breast cancer confers resistance to chemotherapy by evading apoptosis and overcoming G0/G1 arrest Cancer Research. 70: 3177-3177. DOI: 10.1158/1538-7445.Am10-3177 |
0.763 |
|
| 2008 |
Ta HQ, Thomas KS, Schrecengost RS, Bouton AH. A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Research. 68: 8796-804. PMID 18974122 DOI: 10.1158/0008-5472.Can-08-2426 |
0.771 |
|
| 2006 |
Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, Donelan SS, Owen KA, Gibson MA, Shupnik MA, Silva CM, Parsons SJ, Clarke R, Bouton AH. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Research. 66: 7007-15. PMID 16849545 DOI: 10.1158/0008-5472.Can-05-3952 |
0.438 |
|
| Show low-probability matches. |